Boston Scientific has reached an agreement to acquire Penumbra, Inc. for approximately $14.5 billion to enhance its cardiovascular portfolio and address the increasing prevalence of vascular diseases.

Target Information

Boston Scientific Corporation has entered into a definitive agreement to acquire Penumbra, Inc. This transaction is structured as a cash and stock deal, valuing Penumbra at $374 per share and an overall enterprise value of approximately $14.5 billion. Penumbra is recognized for its innovations in medical technology, particularly in mechanical thrombectomy and neurovascular solutions, which address various vascular diseases.

The company has developed an extensive portfolio of devices aimed at managing critical medical conditions, including pulmonary embolism, stroke, and deep vein thrombosis. Their flagship products include the Lightning Bolt® and Lightning Flash® systems, designed for mechanical thrombectomy, which showcases their commitment to improving patient outcomes in the vascular segment.

Industry Overview in the United States

The cardiovascular sector remains a significant area within the U.S. healthcare landscape, where cardiovascular diseases (CVDs) are the leading cause of mortality. The prevalence of these diseases underscores the urgency for inno